While this is a well-known mechanism of juxtacrine cell-to-cell inhibition during developmental angiogenesis, VEGF-dependent Dll4 expression in tumor cells promotes tumor growth by enhancing blood vessel diameter and perfusion, which renders these tumors responsive to anti-VEGF therapy with bevacizumab (Li et al., 2007). This evidence concerns the gene VEGFA and neoplasm.